OncoMatch/Clinical Trials/NCT05123482
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Official title: A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors (BLUESTAR)
Is NCT05123482 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies multiple treatments for breast cancer.
Treatment: AZD8205 · AZD8205 and AZD2936 (Rilvegostomig) · AZD8205 and AZD5305 (saruparib) · AZD8205 and AZD5305 (saruparib) and AZD2936 (rilvegostomig) · AZD8205 in combination with AZD9574 · AZD8205 in combination with AZD9574 plus rilvegostomig (AZD2936) — This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Ovarian Cancer
Endometrial Cancer
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — metastatic or relapsed disease
Participants must have progressed following at least one but no more than 3 prior lines of treatment for metastatic or relapsed disease and have no satisfactory alternative treatment option as judged by the Investigator.
Cannot have received: TOP1 inhibitor (irinotecan, topotecan, trastuzumab deruxtecan)
Previous treatment with any therapy that contains a TOP1i (eg. irinotecan, topotecan, trastuzumab deruxtecan, etc.)
Cannot have received: PARP inhibitor (AZD9574)
Patients have received prior therapy with AZD9574 or more than 1 prior line of any other PARPi-based regimen
Cannot have received: PARP inhibitor
Exception: more than 1 prior line of any other PARPi-based regimen
Patients have received prior therapy with AZD9574 or more than 1 prior line of any other PARPi-based regimen
Cannot have received: rilvegostomig (rilvegostomig)
Previous treatment with rilvegostomig for the cohort treated with rilvegostomig
Lab requirements
Blood counts
Adequate bone marrow function as defined in the protocol
Kidney function
Adequate renal function as defined in the protocol
Liver function
Adequate hepatic function as defined in the protocol
Adequate bone marrow, hepatic, and renal function as defined in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Duarte, California
- Research Site · Irvine, California
- Research Site · Santa Monica, California
- Research Site · Santa Rosa, California
- Research Site · Shreveport, Louisiana
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05123482 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior TOP1 inhibitor, PARP inhibitor, PARP inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages